Author of

• 16831

  +

  P1.06 - Poster Session with Presenters Present (ID 458)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16864

    +

    P1.06-033 - Non-Small Cell Lung Cancer in Young Patients; Clinico-Pathologic Criteria and Prognostic Factors (ID 3809)

    14:30 - 14:30  |  Author(s): F. Abou Elkassem
    • Abstract
    • Slides

    Background:
    A cancer registry was analyzed to determine the clinicopathologic characteristics and prognosis of non-small cell lung cancer (NSCLC) in patients < 45 years old at diagnosis as they were not thoroughly investigated
    
    Methods:
    Among enrolled NSCLC cases attending National Cancer Institute –Cairo (NCI) between 2007-2012, we retrospectively reviewed those who were 45 years old or younger. Data regarding demographics, ECCOG-performance status(PS), histology, grade, stage, chemotherapy type, number of cycles, overall and progression free survival (OS, PFS) were obtained. Pearson’s (X[2]) test , Cox regression and Kaplan-Meier survival curves were used for statistical analysis.
    
    Results:
    Among 99 NSCLC cases, we identified 22cases ≤ 45years. Lower stages were more prevalent among young (77.3%) versus old group(54.5%) p=0.05 Median OS in young versus old group was 18 versus 15 months(p=0.773), while PFS was 4 versus 6 months respectively (p=0.322) In our subgroup analysis(n=22); median age was 42years(30-45years), Nearly three-quarters were males, 40.9% were PS >1. The majority of cases in young group were stage IIIB(77.3.%). Pathology was squamous(40.9%), adenocarcinoma(22.7%), undifferentiated(22.7%) and adenosquamous carcinoma in 4.5% of our cases. Median OS and PFS was 18 and 4 months respectively. Significant difference in OS and PFS was observed among responder versus non responders in multivariate analysis (Figure)
    
    Conclusion:
    Good response to chemotherapy is the best way to prolong survival among young NSCLC cases irrespective of PS, gender, stage or pathology. Figure 1
    
    
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.